Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

Exit

PublicNASDAQ:FURX
Date6/2010
Raised
Post IPO Valuation

General Information

Websitefuriex.com
CategoryBioTech
Phone919-456-7800
Employees24
Founded1998

Offices

Morrisville, USA
3900 Paramount Parkway
Suite 150
Morrisville, NC, 27560
USA

People

Chief Financial Officer and Vice President Strategic Development
President and Chief Medical Officer, Board of Directors
Vice President, Legal Affairs and Secretary
Board of Directors
Board of Directors
Board of Directors
Director, Biostatistics and Psychometrics
Director, Early Drug Development
Show All People

Funding

DEBT TOTAL $15M
Debt, 10/2013
$15M

Tags

Furiex Pharmaceuticals

Furiex Pharmaceuticals, Inc., a drug development company, engages in the compound partnering business primarily in the United States. It collaborates with pharmaceutical and biotechnology companies to enhance the value of their drug candidates by applying its novel approach to drug development. The company’s products under development include Eluxadoline1, a mu opioid receptor agonist and delta opioid receptor antagonist, which is in Phase III clinical trials for the treatment of diarrhea-predominant irritable bowel syndrome; and Avarofloxacin1, a Phase III-ready fluoroquinolone antibiotic for the treatment of acute bacterial skin and skin structure infections.

Recent Milestones

Videos

Screenshots

Stock Price

Sources

  1. Furiex Pharmaceuticals Enters into a Loan Agreement for $15 Million and Restructures Its Existing Secured Loan (bioportfolio.com) [edit]
  2. Furiex Confirms Takeda Receives European Marketing Authorization for VIPIDIA™ (alogliptin), VIPDOMET™ (alogliptin and metformin) and INCRESYNC™ (alogliptin and pioglitazone) (investor.furiex.com) [edit]
Edit This Page
Last Edited 1/9/14

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize »

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy